Intech Biopharm Past Earnings Performance
Past criteria checks 0/6
Intech Biopharm's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 10.6% per year.
Key information
-6.2%
Earnings growth rate
3.2%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 10.6% |
Return on equity | -28.9% |
Net Margin | -1,307.6% |
Next Earnings Update | 03 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Intech Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 26 | -338 | 52 | 104 |
30 Sep 23 | 25 | -339 | 50 | 110 |
30 Jun 23 | 20 | -328 | 53 | 103 |
31 Mar 23 | 16 | -340 | 52 | 120 |
31 Dec 22 | 24 | -328 | 52 | 119 |
30 Sep 22 | 33 | -309 | 53 | 115 |
30 Jun 22 | 44 | -305 | 50 | 130 |
31 Mar 22 | 43 | -303 | 49 | 128 |
31 Dec 21 | 39 | -302 | 48 | 127 |
30 Sep 21 | 31 | -287 | 41 | 108 |
30 Jun 21 | 21 | -281 | 43 | 88 |
31 Mar 21 | 23 | -258 | 42 | 72 |
31 Dec 20 | 21 | -250 | 39 | 62 |
30 Sep 20 | 19 | -270 | 41 | 74 |
30 Jun 20 | 20 | -285 | 46 | 80 |
31 Mar 20 | 18 | -303 | 47 | 85 |
31 Dec 19 | 17 | -311 | 59 | 95 |
30 Sep 19 | 18 | -280 | 86 | 84 |
30 Jun 19 | 17 | -255 | 111 | 83 |
31 Mar 19 | 17 | -240 | 144 | 82 |
31 Dec 18 | 17 | -222 | 161 | 79 |
30 Sep 18 | 17 | -237 | 163 | 92 |
30 Jun 18 | 17 | -266 | 163 | 121 |
31 Mar 18 | 16 | -249 | 159 | 111 |
31 Dec 17 | 17 | -239 | 150 | 106 |
30 Sep 17 | 17 | -203 | 129 | 92 |
30 Jun 17 | 15 | -145 | 105 | 57 |
31 Mar 17 | 14 | -133 | 83 | 63 |
31 Dec 16 | 12 | -125 | 72 | 66 |
30 Sep 16 | 9 | -130 | 66 | 67 |
30 Jun 16 | 10 | -140 | 64 | 73 |
31 Mar 16 | 10 | -128 | 60 | 70 |
31 Dec 15 | 10 | -116 | 56 | 68 |
30 Sep 15 | 9 | -103 | 47 | 69 |
30 Jun 15 | 9 | -89 | 39 | 70 |
31 Mar 15 | 9 | -84 | 32 | 72 |
31 Dec 14 | 9 | -79 | 25 | 74 |
30 Sep 14 | 8 | -64 | 19 | 65 |
30 Jun 14 | 8 | -49 | 14 | 56 |
31 Mar 14 | 8 | -33 | 10 | 42 |
31 Dec 13 | 7 | -17 | 5 | 28 |
Quality Earnings: 6461 is currently unprofitable.
Growing Profit Margin: 6461 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6461 is unprofitable, and losses have increased over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare 6461's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6461 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 6461 has a negative Return on Equity (-28.94%), as it is currently unprofitable.